Earlier this week we highlighted how click chemistry technology has enabled the development of a protodrug platform with inert polymers for more targeted delivery of chemotherapeutic drugs.
Similarly, another related approach we can consider to reduce unwanted adverse events is the prodrug concept. In this situation, a potent chemotherapy is activated in the tumour where it is most needed thereby reducing the toxic effects on normal cells and improving tolerability for people receiving the therapy.
Can prodrug technology deliver potent alkylator chemotherapy in a much more targeted fashion in the tumour?
One of the well known challenges and limitations associated with standard alkylating chemotherapies has always been the indiscriminate toxicities resulting from systemic administration – they impact both cancer cells and normal cells with impunity.
What if we could develop a more targeted chemotherapy approach?
This might be useful for some people with advanced cancer where a modicum of disease control is needed, so how would we go about achieving this aim?
Here’s one way to potentially accomplish the task…
To learn more about these insights and get a heads up on our latest oncology expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
We have written about a huge variety of different approaches to cancer research since 2006 but few are as intriguing as using pathogen-based approaches involving viruses or bacteria to stimulate or re-activate the immune system. After all, when such foreign bodies break through the physical barriers and enter the bloodstream, the immune system instantly springs into action to tackle them.
Can this knowledge be used effectively in the design of anti-cancer therapeutics?
We have seen some promising initial results with oncolytic viruses, but what about bacterial based approaches? Can a different approach to drug scaffolds yield improved results?
Here, we look through the window at a novel platform using immunotoxins in early development that may well pique a few people’s interest and offer our latest thought leader interview discussing the approach…
To learn more from our latest thought leader interview, conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.